Lantern Pharma Inc Equity-NMS: LTRN

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$4.2

Open :

$4.19

Today's high :

$4.38

Today's low :

$4.14

52W low :

$2.55

52W high :

$6.118

EPS(TTM): :

-1.78

Shares O/S :

10.8 M

Market cap :

46.55 M

What is the share price of Lantern Pharma Inc today?

Lantern Pharma Inc (LTRN) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Lantern Pharma Inc?

Yes, Indian Investors can invest in the Lantern Pharma Inc (LTRN) Share by opening an international trading account with Angel One.

How can I purchase Lantern Pharma Inc shares in India?

Purchasing Lantern Pharma Inc (LTRN) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Lantern Pharma Inc (LTRN) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Lantern Pharma Inc?

Yes, you can purchase fractional shares of Lantern Pharma Inc (LTRN) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Lantern Pharma Inc?

The market capitalization of Lantern Pharma Inc on January 1, 1970, is $0.

What documents are required to invest in Lantern Pharma Inc stocks?

In order to invest in Lantern Pharma Inc (LTRN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.